Skip to content

Study · Animal study (in vivo) · mouse · 2023

7 results

The single-chain relaxin mimetic, B7-33, maintains the cardioprotective effects of relaxin and more rapidly reduces left ventricular fibrosis compared to perindopril in an experimental model of cardiomyopathy.

Alam F, Gaspari TA, Kemp-Harper BK, Low E, Aw A, Ferens D, Spizzo I, Jefferis AM, Praveen P, Widdop RE, Bathgate RAD, Hossain MA, Samuel CS

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie6 Feb 2023Cited by 12 (Europe PMC)

PMID36753958 (opens in a new tab)DOI10.1016/j.biopha.2023.114370 (opens in a new tab)PepBankPUB-36753958
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice with cardiomyopathy, B7‑33 reduced left ventricular fibrosis equivalently to relaxin.

    In plain wordsIn mice with cardiomyopathy, B7‑33 and relaxin reduced heart fibrosis to a similar extent.

    Peptide
    B7-33 (single-chain relaxin-2 analog)
    Outcome
    DecreaseLeft ventricular fibrosis
    Study

    mousen: not reported in source

    Isoprenaline-induced cardiomyopathy in adult male 129sv mice
    Comparator
    Relaxin
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    0.25 mg/kg/day · subcutaneous · days 7-14 post-injuryAs given in this study (mouse).

    Source sentences

    Summary
    Both B7-33 and RLX equivalently reduced LV fibrosis and normalised the ISO-induced LV inflammation and cardiomyocyte hypertrophy, whilst restoring blood vessel density and aortic contractility.
    1 context sentence
    Summary · context
    Adult male 129sv mice were subjected to isoprenaline (ISO; 25 mg/kg/day, s.c)-induced cardiomyopathy, then s.c-treated with either RLX (0.5 mg/kg/day), B7-33 (0.25 mg/kg/day; equivalent dose corrected for MW) or perindopril (1 mg/kg/day) from days 7-14 post-injury.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In mice with cardiomyopathy, B7‑33 normalized isoprenaline-induced left ventricular inflammation.

    In plain wordsIn mice with cardiomyopathy, B7‑33 normalized injury-related heart inflammation.

    Peptide
    B7-33 (single-chain relaxin-2 analog)
    Outcome
    DecreaseLeft ventricular inflammation
    Study

    mousen: not reported in source

    Isoprenaline-induced cardiomyopathy in adult male 129sv mice
    Outcome group
    Inflammation markers · Cardiovascular
    Studied dose
    0.25 mg/kg/day · subcutaneous · days 7-14 post-injuryAs given in this study (mouse).

    Source sentences

    Summary
    Both B7-33 and RLX equivalently reduced LV fibrosis and normalised the ISO-induced LV inflammation and cardiomyocyte hypertrophy, whilst restoring blood vessel density and aortic contractility.
    1 context sentence
    Summary · context
    Adult male 129sv mice were subjected to isoprenaline (ISO; 25 mg/kg/day, s.c)-induced cardiomyopathy, then s.c-treated with either RLX (0.5 mg/kg/day), B7-33 (0.25 mg/kg/day; equivalent dose corrected for MW) or perindopril (1 mg/kg/day) from days 7-14 post-injury.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In mice with cardiomyopathy, B7‑33 normalized isoprenaline-induced cardiomyocyte hypertrophy.

    In plain wordsIn mice with cardiomyopathy, B7‑33 normalized injury-related heart cell enlargement.

    Peptide
    B7-33 (single-chain relaxin-2 analog)
    Outcome
    DecreaseCardiomyocyte hypertrophy
    Study

    mousen: not reported in source

    Isoprenaline-induced cardiomyopathy in adult male 129sv mice
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    0.25 mg/kg/day · subcutaneous · days 7-14 post-injuryAs given in this study (mouse).

    Source sentences

    Summary
    Both B7-33 and RLX equivalently reduced LV fibrosis and normalised the ISO-induced LV inflammation and cardiomyocyte hypertrophy, whilst restoring blood vessel density and aortic contractility.
    1 context sentence
    Summary · context
    Adult male 129sv mice were subjected to isoprenaline (ISO; 25 mg/kg/day, s.c)-induced cardiomyopathy, then s.c-treated with either RLX (0.5 mg/kg/day), B7-33 (0.25 mg/kg/day; equivalent dose corrected for MW) or perindopril (1 mg/kg/day) from days 7-14 post-injury.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In mice with cardiomyopathy, B7‑33 restored blood vessel density.

    In plain wordsIn mice with cardiomyopathy, B7‑33 restored blood vessel density.

    Peptide
    B7-33 (single-chain relaxin-2 analog)
    Outcome
    IncreaseBlood vessel density
    Study

    mousen: not reported in source

    Isoprenaline-induced cardiomyopathy in adult male 129sv mice
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    0.25 mg/kg/day · subcutaneous · days 7-14 post-injuryAs given in this study (mouse).

    Source sentences

    Summary
    Both B7-33 and RLX equivalently reduced LV fibrosis and normalised the ISO-induced LV inflammation and cardiomyocyte hypertrophy, whilst restoring blood vessel density and aortic contractility.
    1 context sentence
    Summary · context
    Adult male 129sv mice were subjected to isoprenaline (ISO; 25 mg/kg/day, s.c)-induced cardiomyopathy, then s.c-treated with either RLX (0.5 mg/kg/day), B7-33 (0.25 mg/kg/day; equivalent dose corrected for MW) or perindopril (1 mg/kg/day) from days 7-14 post-injury.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In mice with cardiomyopathy, B7‑33 restored the increased aortic contractility toward normal.

    In plain wordsIn mice with cardiomyopathy, B7‑33 restored abnormally increased aortic contraction toward normal.

    Peptide
    B7-33 (single-chain relaxin-2 analog)
    Outcome
    DecreaseAortic contractility
    Study

    mousen: not reported in source

    Isoprenaline-induced cardiomyopathy in adult male 129sv mice
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    0.25 mg/kg/day · subcutaneous · days 7-14 post-injuryAs given in this study (mouse).

    Source sentences

    Summary
    Both B7-33 and RLX equivalently reduced LV fibrosis and normalised the ISO-induced LV inflammation and cardiomyocyte hypertrophy, whilst restoring blood vessel density and aortic contractility.
    2 context sentences
    Summary · context
    ISO-injured mice had significantly increased LV inflammation, cardiomyocyte hypertrophy, fibrosis, vascular rarefaction and aortic contractility in the absence of any changes in BW or SBP at day 14 post-injury.
    Summary · context
    Adult male 129sv mice were subjected to isoprenaline (ISO; 25 mg/kg/day, s.c)-induced cardiomyopathy, then s.c-treated with either RLX (0.5 mg/kg/day), B7-33 (0.25 mg/kg/day; equivalent dose corrected for MW) or perindopril (1 mg/kg/day) from days 7-14 post-injury.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In mice with cardiomyopathy, B7‑33 reduced fibrosis while perindopril did not.

    In plain wordsIn mice with cardiomyopathy, B7‑33 reduced heart fibrosis, while perindopril did not.

    Peptide
    B7-33 (single-chain relaxin-2 analog)
    Outcome
    DecreaseLeft ventricular fibrosis versus perindopril
    Study

    mousen: not reported in source

    Isoprenaline-induced cardiomyopathy in adult male 129sv mice
    Comparator
    Perindopril
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    0.25 mg/kg/day · subcutaneous · days 7-14 post-injuryAs given in this study (mouse).

    Source sentences

    Summary
    Both B7-33 and RLX equivalently reduced LV fibrosis and normalised the ISO-induced LV inflammation and cardiomyocyte hypertrophy, whilst restoring blood vessel density and aortic contractility.
    2 context sentences
    Summary · context
    Comparatively, perindopril lowered SBP and the ISO-induced LV inflammation and vascular rarefaction, but not fibrosis or hypertrophy.
    Summary · context
    Adult male 129sv mice were subjected to isoprenaline (ISO; 25 mg/kg/day, s.c)-induced cardiomyopathy, then s.c-treated with either RLX (0.5 mg/kg/day), B7-33 (0.25 mg/kg/day; equivalent dose corrected for MW) or perindopril (1 mg/kg/day) from days 7-14 post-injury.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In mice with cardiomyopathy, B7‑33 normalized cardiomyocyte hypertrophy, while perindopril did not reduce hypertrophy.

    In plain wordsIn mice with cardiomyopathy, B7‑33 normalized heart cell enlargement, while perindopril did not reduce it.

    Peptide
    B7-33 (single-chain relaxin-2 analog)
    Outcome
    DecreaseCardiomyocyte hypertrophy versus perindopril
    Study

    mousen: not reported in source

    Isoprenaline-induced cardiomyopathy in adult male 129sv mice
    Comparator
    Perindopril
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    0.25 mg/kg/day · subcutaneous · days 7-14 post-injuryAs given in this study (mouse).

    Source sentences

    Summary
    Both B7-33 and RLX equivalently reduced LV fibrosis and normalised the ISO-induced LV inflammation and cardiomyocyte hypertrophy, whilst restoring blood vessel density and aortic contractility.
    2 context sentences
    Summary · context
    Comparatively, perindopril lowered SBP and the ISO-induced LV inflammation and vascular rarefaction, but not fibrosis or hypertrophy.
    Summary · context
    Adult male 129sv mice were subjected to isoprenaline (ISO; 25 mg/kg/day, s.c)-induced cardiomyopathy, then s.c-treated with either RLX (0.5 mg/kg/day), B7-33 (0.25 mg/kg/day; equivalent dose corrected for MW) or perindopril (1 mg/kg/day) from days 7-14 post-injury.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.